Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Background Atrial fibrillation (AF) remains the most common form of cardiac arrhythmia.
Management of AF aims to reduce the risk of stroke, heart failure and premature mortality via …

Background: It is unclear whether warfarin treatment with high time in therapeutic range
(TTR) is as effective and safe as non-vitamin K antagonist oral anticoagulants (NOACs). It is …

Background: In the clinical setting, the economic benefits of direct oral anticoagulants
(DOACs) in elderly patients with atrial fibrillation (AF) remain unclear. This study aimed to …

Background: Warfarin remains the most commonly used oral anticoagulant (OAC) in
Thailand for stroke prevention among patients with non-valvular atrial fibrillation (NVAF) …

Objective To assess the cost-effectiveness of pharmacogenomics (PGx)-based warfarin (ie,
warfarin dosing following genetic testing), apixaban, and rivaroxaban oral anticoagulation …

Abstract Introduction Novel oral anticoagulants (NOACs) and warfarin care bundles (eg
genotyping, patient self-testing or self-management) are alternatives to usual warfarin care …

Background: Several studies have shown the cost-effectiveness of direct oral anticoagulants
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …

Background Direct oral anticoagulants (DOACs) are commonly used to prevent stroke and
systemic embolism in patients with atrial fibrillation (AF). However, studies into their …

Background Cost-effectiveness analyses (CEAs) on prevention of non-communicable
diseases (NCDs) are necessary to guide decision makers to allocate scarce healthcare …